Randomized Phase II/III Adjuvant Trial Evaluating Feasibility of Standard (A) vs. Customized Treatment (B) in Stage II or Stage IIIA Non-N2, Non-squamous Non Small Cell Lung Cancer (NSCLC).
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Feasibility (% of patients having started the treatment before 2 months after the surgery, with the biological results EGFR and ERCC1)
Jean-Charles SORIA, Pr
Institut Gustave Roussy (IGR)
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)